Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 1

van Alderwerelt van Rosenburgh, Iris K.; Lu, David M.; Grant, Michael J.; Stayrook, Steven E.; Phadke, Manali; Walther, Zenta; Goldberg, Sarah B.; Politi, Katerina; Lemmon, Mark A.; Ashtekar, Kumar D.; Tsutsui, Yuko

doi:10.1038/s41467-022-34398-z

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 1

Journal Article · 01 November 2022 · Nat. Commun.

DOI:https://doi.org/10.1038/s41467-022-34398-z· OSTI ID:1901311

van Alderwerelt van Rosenburgh, Iris K.; Lu, David M.; Grant, Michael J.; Stayrook, Steven E.; Phadke, Manali; Walther, Zenta; Goldberg, Sarah B.; Politi, Katerina; Lemmon, Mark A.; Ashtekar, Kumar D.; Tsutsui, Yuko

Research Organization:: Advanced Photon Source (APS), Argonne National Laboratory (ANL), Argonne, IL (US)

Sponsoring Organization:: DOE - Office Of Science; NIGMS; NIH

OSTI ID:: 1901311

Journal Information:: Nat. Commun., Journal Name: Nat. Commun. Vol. 13

Country of Publication:: United States

Language:: ENGLISH

References (75)

Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib Carey, Kendall D.; Garton, Andrew J.; Romero, Maria S. Cancer Research, Vol. 66, Issue 16 https://doi.org/10.1158/0008-5472.CAN-06-0453	journal	August 2006
Conformational Transitions in the Membrane Scaffold Protein of Phospholipid Bilayer Nanodiscs Morgan, Christopher R.; Hebling, Christine M.; Rand, Kasper D. Molecular & Cellular Proteomics, Vol. 10, Issue 9 https://doi.org/10.1074/mcp.M111.010876	journal	September 2011
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2 Foster, Scott A.; Whalen, Daniel M.; Özen, Ayşegül Cancer Cell, Vol. 29, Issue 4 https://doi.org/10.1016/j.ccell.2016.02.010	journal	April 2016
Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib Jackman, David M.; Yeap, Beow Y.; Sequist, Lecia V. Clinical Cancer Research, Vol. 12, Issue 13 https://doi.org/10.1158/1078-0432.CCR-06-0462	journal	July 2006
Multistrip Western Blotting: A Tool for Comparative Quantitative Analysis of Multiple Proteins Aksamitiene, Edita; Hoek, Jan B.; Kiyatkin, Anatoly Methods in Molecular Biology https://doi.org/10.1007/978-1-4939-2694-7_23	book	January 2015
Probing protein interactions with hydrogen/deuterium exchange and mass spectrometry—A review Percy, Andrew J.; Rey, Martial; Burns, Kyle M. Analytica Chimica Acta, Vol. 721 https://doi.org/10.1016/j.aca.2012.01.037	journal	April 2012
ALK Mutations Confer Differential Oncogenic Activation and Sensitivity to ALK Inhibition Therapy in Neuroblastoma Bresler, Scott C.; Weiser, Daniel A.; Huwe, Peter J. Cancer Cell, Vol. 26, Issue 5 https://doi.org/10.1016/j.ccell.2014.09.019	journal	November 2014
An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor Zhang, Xuewu; Gureasko, Jodi; Shen, Kui Cell, Vol. 125, Issue 6 https://doi.org/10.1016/j.cell.2006.05.013	journal	June 2006
Assessment of differences in the conformational flexibility of hepatitis B virus core-antigen and e-antigen by hydrogen deuterium exchange-mass spectrometry: Flexibility of the HBV Core-Antigen and e-Antigen Bereszczak, Jessica Z.; Watts, Norman R.; Wingfield, Paul T. Protein Science, Vol. 23, Issue 7 https://doi.org/10.1002/pro.2470	journal	April 2014
COSMIC: the Catalogue Of Somatic Mutations In Cancer Tate, John G.; Bamford, Sally; Jubb, Harry C. Nucleic Acids Research, Vol. 47, Issue D1 https://doi.org/10.1093/nar/gky1015	journal	October 2018
Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies Zhai, Xiang; Ward, Richard A.; Doig, Peter Biochemistry, Vol. 59, Issue 14 https://doi.org/10.1021/acs.biochem.0c00104	journal	March 2020
AACR Project GENIE: Powering Precision Medicine through an International Consortium No authors listed Cancer Discovery, Vol. 7, Issue 8 https://doi.org/10.1158/2159-8290.CD-17-0151	journal	August 2017
Molecular characteristics and clinical outcomes of EGFR exon 19 indel subtypes to EGFR TKIs in NSCLC patients Su, Jian; Zhong, Wenzhao; Zhang, Xuchao Oncotarget, Vol. 8, Issue 67 https://doi.org/10.18632/oncotarget.22768	journal	November 2017
Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations Li, Miaomiao; Li, Mengrong; Xie, Yanjie Molecules, Vol. 27, Issue 12 https://doi.org/10.3390/molecules27123844	journal	June 2022
Structure-based classification predicts drug response in EGFR-mutant NSCLC Robichaux, Jacqulyne P.; Le, Xiuning; Vijayan, R. S. K. Nature, Vol. 597, Issue 7878 https://doi.org/10.1038/s41586-021-03898-1	journal	September 2021
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Yun, C. -H.; Mengwasser, K. E.; Toms, A. V. Proceedings of the National Academy of Sciences, Vol. 105, Issue 6 https://doi.org/10.1073/pnas.0709662105	journal	January 2008
EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients Sutiman, Natalia; Tan, Shao Weng; Tan, Eng Huat Journal of Thoracic Oncology, Vol. 12, Issue 3 https://doi.org/10.1016/j.jtho.2016.11.2225	journal	March 2017
Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR Chung, Kuei-Pin; Wu, Shang-Gin; Wu, Jenn-Yu Clinical Cancer Research, Vol. 18, Issue 12 https://doi.org/10.1158/1078-0432.CCR-11-2353	journal	June 2012
Phaser crystallographic software McCoy, Airlie J.; Grosse-Kunstleve, Ralf W.; Adams, Paul D. Journal of Applied Crystallography, Vol. 40, Issue 4 https://doi.org/10.1107/S0021889807021206	journal	July 2007
Analytical Aspects of Hydrogen Exchange Mass Spectrometry Engen, John R.; Wales, Thomas E. Annual Review of Analytical Chemistry, Vol. 8, Issue 1 https://doi.org/10.1146/annurev-anchem-062011-143113	journal	July 2015
Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma Improta, Giuseppina; Zupa, Angela; Natalicchio, Maria Iole Medical Oncology, Vol. 35, Issue 3 https://doi.org/10.1007/s12032-018-1078-7	journal	January 2018
The CCP4 suite programs for protein crystallography No authors listed Acta Crystallographica Section D Biological Crystallography, Vol. 50, Issue 5, p. 760-763 https://doi.org/10.1107/S0907444994003112	journal	September 1994
Molecular Characteristics and Clinical Outcomes of EGFR Exon 19 C-Helix Deletion in Non–Small Cell Lung Cancer and Response to EGFR TKIs Xu, Chun-wei; Lei, Lei; Wang, Wen-xian Translational Oncology, Vol. 13, Issue 9 https://doi.org/10.1016/j.tranon.2020.100791	journal	September 2020
Non‐small cell lung cancer harboring a rareEGFRL747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): A case report Huang, Jing; Wang, Yiyin; Zhai, Yachao Thoracic Cancer, Vol. 9, Issue 6 https://doi.org/10.1111/1759-7714.12637	journal	April 2018
Impact of EGFR exon 19 deletion subtypes on clinical outcomes in EGFR-TKI-Treated advanced non-small-cell lung cancer Huang, Le-Tian; Zhang, Shu-Ling; Han, Cheng-Bo Lung Cancer, Vol. 166 https://doi.org/10.1016/j.lungcan.2022.01.014	journal	April 2022
The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences Perez-Riverol, Yasset; Bai, Jingwen; Bandla, Chakradhar Nucleic Acids Research, Vol. 50, Issue D1 https://doi.org/10.1093/nar/gkab1038	journal	November 2021
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Lynch, Thomas J.; Bell, Daphne W.; Sordella, Raffaella New England Journal of Medicine, Vol. 350, Issue 21 https://doi.org/10.1056/NEJMoa040938	journal	May 2004
Optimal Sox-based fluorescent chemosensor design for serine/threonine protein kinases Shults, Melissa D.; Carrico-Moniz, Dora; Imperiali, Barbara Analytical Biochemistry, Vol. 352, Issue 2 https://doi.org/10.1016/j.ab.2006.03.003	journal	May 2006
Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma Tian, Yingying; Zhao, Jiuzhou; Ren, Pengfei PLOS ONE, Vol. 13, Issue 11 https://doi.org/10.1371/journal.pone.0201682	journal	November 2018
Epidermal growth factor receptor mutations in lung cancer Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey Nature Reviews Cancer, Vol. 7, Issue 3 https://doi.org/10.1038/nrc2088	journal	March 2007
Escherichia coli Processivity Clamp β from DNA Polymerase III Is Dynamic in Solution Fang, Jing; Engen, John R.; Beuning, Penny J. Biochemistry, Vol. 50, Issue 26 https://doi.org/10.1021/bi200580b	journal	July 2011
Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790M Wang, Yurong; Zheng, Ruipan; Hu, Peizhu BMC Cancer, Vol. 21, Issue 1 https://doi.org/10.1186/s12885-021-08942-x	journal	November 2021
The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma Truini, Anna; Starrett, Jacqueline H.; Stewart, Tyler Clinical Cancer Research, Vol. 25, Issue 21 https://doi.org/10.1158/1078-0432.CCR-19-0780	journal	November 2019
Structural basis of the effect of activating mutations on the EGF receptor Galdadas, Ioannis; Carlino, Luca; Ward, Richard A. eLife, Vol. 10 https://doi.org/10.7554/eLife.65824	journal	July 2021
Structural characterization of EGFR exon 19 deletion mutation using molecular dynamics simulation Tamirat, Mahlet Z.; Koivu, Marika; Elenius, Klaus PLOS ONE, Vol. 14, Issue 9 https://doi.org/10.1371/journal.pone.0222814	journal	September 2019
The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation–Positive Non–Small Cell Lung Cancer: Status in 2016 Tan, Daniel S. W.; Yom, Sue S.; Tsao, Ming S. Journal of Thoracic Oncology, Vol. 11, Issue 7 https://doi.org/10.1016/j.jtho.2016.05.008	journal	July 2016
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC Ramalingam, Suresh S.; Vansteenkiste, Johan; Planchard, David New England Journal of Medicine, Vol. 382, Issue 1 https://doi.org/10.1056/NEJMoa1913662	journal	January 2020
Epidermal Growth Factor Receptor Mutants from Human Lung Cancers Exhibit Enhanced Catalytic Activity and Increased Sensitivity to Gefitinib Mulloy, Roseann; Ferrand, Audrey; Kim, Youngjoo Cancer Research, Vol. 67, Issue 5 https://doi.org/10.1158/0008-5472.CAN-06-4293	journal	March 2007
Worldwide Frequency of Commonly Detected EGFR Mutations Graham, Rondell P.; Treece, Amanda L.; Lindeman, Neal I. Archives of Pathology & Laboratory Medicine, Vol. 142, Issue 2 https://doi.org/10.5858/arpa.2016-0579-CP	journal	November 2017
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor Yoshikawa, S.; Kukimoto-Niino, M.; Parker, L. Oncogene, Vol. 32, Issue 1 https://doi.org/10.1038/onc.2012.21	journal	February 2012
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer Eck, Michael J.; Yun, Cai-Hong Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics, Vol. 1804, Issue 3 https://doi.org/10.1016/j.bbapap.2009.12.010	journal	March 2010
Heterogeneous Response to First-Generation Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers with Different EGFR Exon 19 Mutations Xu, Haiyan; Li, Weihua; Yang, Guangjian Targeted Oncology, Vol. 15, Issue 3 https://doi.org/10.1007/s11523-020-00722-0	journal	May 2020
EX1 Hydrogen Exchange and Protein Folding ^† Ferraro, Debra M.; Lazo, Noel D.; Robertson, Andrew D. Biochemistry, Vol. 43, Issue 3 https://doi.org/10.1021/bi035943y	journal	January 2004
Coot model-building tools for molecular graphics Emsley, Paul; Cowtan, Kevin Acta Crystallographica Section D Biological Crystallography, Vol. 60, Issue 12, p. 2126-2132 https://doi.org/10.1107/S0907444904019158	journal	November 2004
Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers Roskoski, Robert Pharmacological Research, Vol. 139 https://doi.org/10.1016/j.phrs.2018.11.014	journal	January 2019
Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction Yung-Chi, Cheng; Prusoff, William H. Biochemical Pharmacology, Vol. 22, Issue 23 https://doi.org/10.1016/0006-2952(73)90196-2	journal	December 1973
Towards automated crystallographic structure refinement with phenix.refine Afonine, Pavel V.; Grosse-Kunstleve, Ralf W.; Echols, Nathaniel Acta Crystallographica Section D Biological Crystallography, Vol. 68, Issue 4 https://doi.org/10.1107/S0907444912001308	journal	March 2012
The PDB_REDO server for macromolecular structure model optimization Joosten, Robbie P.; Long, Fei; Murshudov, Garib N. IUCrJ, Vol. 1, Issue 4 https://doi.org/10.1107/S2052252514009324	journal	May 2014
Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912) Foster, Jennifer H.; Voss, Stephan D.; Hall, David C. Clinical Cancer Research, Vol. 27, Issue 13 https://doi.org/10.1158/1078-0432.CCR-20-4224	journal	February 2021
Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments Masson, Glenn R.; Burke, John E.; Ahn, Natalie G. Nature Methods, Vol. 16, Issue 7 https://doi.org/10.1038/s41592-019-0459-y	journal	June 2019
Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles Journal of Biological Chemistry, Vol. 277, Issue 48 https://doi.org/10.1074/jbc.M207135200	journal	August 2002
Highly accurate protein structure prediction for the human proteome Tunyasuvunakool, Kathryn; Adler, Jonas; Wu, Zachary Nature, Vol. 596, Issue 7873 https://doi.org/10.1038/s41586-021-03828-1	journal	July 2021
XDS Kabsch, Wolfgang Acta Crystallographica Section D Biological Crystallography, Vol. 66, Issue 2 https://doi.org/10.1107/S0907444909047337	journal	January 2010
ColabFold: making protein folding accessible to all Mirdita, Milot; Schütze, Konstantin; Moriwaki, Yoshitaka Nature Methods, Vol. 19, Issue 6 https://doi.org/10.1038/s41592-022-01488-1	journal	May 2022
Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain Pao, William; Miller, Vincent A.; Politi, Katerina A. PLoS Medicine, Vol. 2, Issue 3 https://doi.org/10.1371/journal.pmed.0020073	journal	February 2005
Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib Riely, Gregory J.; Pao, William; Pham, DuyKhanh Clinical Cancer Research, Vol. 12, Issue 3 https://doi.org/10.1158/1078-0432.CCR-05-1846	journal	February 2006
The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors Yang, Guangjian; Liu, Chengming; Hu, Jiaqi Frontiers in Oncology, Vol. 12 https://doi.org/10.3389/fonc.2022.843299	journal	February 2022
Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations Liang, Sheng-Kai; Ko, Jen-Chung; Yang, James Chih-Hsin Lung Cancer, Vol. 133 https://doi.org/10.1016/j.lungcan.2019.05.019	journal	July 2019
Deletion Mutations Keep Kinase Inhibitors in the Loop Freed, Daniel M.; Park, Jin H.; Radhakrishnan, Ravi Cancer Cell, Vol. 29, Issue 4 https://doi.org/10.1016/j.ccell.2016.03.017	journal	April 2016
Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain Park, Jin H.; Liu, Yingting; Lemmon, Mark A. Biochemical Journal, Vol. 448, Issue 3 https://doi.org/10.1042/BJ20121513	journal	November 2012
Association of Exon 19 and 21 EGFR Mutation Patterns with Treatment Outcome after First-Line Tyrosine Kinase Inhibitor in Metastatic Non–Small-Cell Lung Cancer Lee, Victor H. F.; Tin, Vicky P. C.; Choy, Tim-shing Journal of Thoracic Oncology, Vol. 8, Issue 9 https://doi.org/10.1097/JTO.0b013e31829f684a	journal	September 2013
Protein Analysis by Hydrogen Exchange Mass Spectrometry Hoofnagle, Andrew N.; Resing, Katheryn A.; Ahn, Natalie G. Annual Review of Biophysics and Biomolecular Structure, Vol. 32, Issue 1 https://doi.org/10.1146/annurev.biophys.32.110601.142417	journal	June 2003
Modeling of Receptor Tyrosine Kinase Signaling: Computational and Experimental Protocols Fey, Dirk; Aksamitiene, Edita; Kiyatkin, Anatoly Methods in Molecular Biology https://doi.org/10.1007/978-1-4939-7154-1_27	book	January 2017
Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanisms of drug resistance Schwartz, P. A.; Kuzmic, P.; Solowiej, J. Proceedings of the National Academy of Sciences, Vol. 111, Issue 1 https://doi.org/10.1073/pnas.1313733111	journal	December 2013
Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer Peng, Xingzhou; Long, Xiaoyan; Liu, Li European Journal of Cancer, Vol. 141 https://doi.org/10.1016/j.ejca.2020.10.005	journal	December 2020
A multicenter-retrospective study of non-small-cell lung carcinoma harboring uncommon epidermal growth factor receptor (EGFR) mutations: different subtypes of EGFR exon 19 deletion-insertions exhibit the clinical characteristics and prognosis of non-small cell lung carcinoma Chen, Ying; Xu, Jinhe; Zhang, Lei Translational Lung Cancer Research, Vol. 11, Issue 2 https://doi.org/10.21037/tlcr-22-48	journal	February 2022
Dynamics of the Tec-family tyrosine kinase SH3 domains Roberts, Justin M.; Tarafdar, Sreya; Joseph, Raji E. Protein Science, Vol. 25, Issue 4 https://doi.org/10.1002/pro.2887	journal	March 2016
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal Gristina, Valerio; Malapelle, Umberto; Galvano, Antonio Cancer Treatment Reviews, Vol. 85 https://doi.org/10.1016/j.ctrv.2020.101994	journal	April 2020
Structural Basis of AZD9291 Selectivity for EGFR T790M Yan, Xiao-E; Ayaz, Pelin; Zhu, Su-Jie Journal of Medicinal Chemistry, Vol. 63, Issue 15 https://doi.org/10.1021/acs.jmedchem.0c00891	journal	July 2020
Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma Kim, Seok-Young; Kim, Sang-Min; Lim, Sumin Clinical Cancer Research, Vol. 27, Issue 15 https://doi.org/10.1158/1078-0432.CCR-20-5026	journal	June 2021
Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma Bresler, Scott C.; Wood, Andrew C.; Haglund, Elizabeth A. Science Translational Medicine, Vol. 3, Issue 108 https://doi.org/10.1126/scitranslmed.3002950	journal	November 2011
Exon 19 L747P mutation presented as a primary resistance to EGFR-TKI: a case report Wang, Yu-Ting; Ning, Wei-Wei; Li, Jing Journal of Thoracic Disease, Vol. 8, Issue 7 https://doi.org/10.21037/jtd.2016.05.95	journal	July 2016
The impact of EGFR exon 19 deletion subtypes on clinical outcomes in non-small cell lung cancer Zhao, Chao; Jiang, Tao; Li, Jiayu Translational Lung Cancer Research, Vol. 9, Issue 4 https://doi.org/10.21037/tlcr-19-359	journal	August 2020
Recognition-Domain Focused Chemosensors: Versatile and Efficient Reporters of Protein Kinase Activity Luković, Elvedin; González-Vera, Juan A.; Imperiali, Barbara Journal of the American Chemical Society, Vol. 130, Issue 38 https://doi.org/10.1021/ja8046188	journal	August 2008
Cumulative mechanism of several major imatinib-resistant mutations in Abl kinase Hoemberger, Marc; Pitsawong, Warintra; Kern, Dorothee Proceedings of the National Academy of Sciences, Vol. 117, Issue 32 https://doi.org/10.1073/pnas.1919221117	journal	July 2020

Similar Records

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Journal Article · 2015 · Cancer Cell · OSTI ID:1222792

Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors

Journal Article · 2020 · J. Med. Chem. · OSTI ID:1630324

Structures of Lung Cancer-Derived EGFR Mutants and Inhibitor Complexes: Mechanism of Activation and Insights into Differential Inhibitor Sensitivity

Journal Article · 2006 · Cancer Cell · OSTI ID:930369

Biochemical and structural basis for differential inhibitor sensitivity of EGFR with distinct exon 1

Citation Formats

References (75)

Similar Records

Related Subjects